New melanoma cancer drug in development shows promise
University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma
The relationship between iRhom2 and KRAS proteins
/in Front page /by Oxford CentreDevelopment Fund winners from the Freeman group are investigating newly discovered proteins and their potential as targets for new cancer treatments
The impact of COVID-19 on cancer patients
/in Front page /by Oxford CentreA new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has investigated which cancer patients may be more susceptible to the impacts of coronavirus
IL-22 pathway linked to poor prognosis in colon cancer
/in Front page /by Oxford CentreResearch shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer
Oxford lymphoid study group established
/in Front page /by Oxford CentreThe new Oxford Lymphoid Disorder Study Group, chaired by Dr Graham Collins, will be launched this September in Blood Cancer Awareness Month
The relationship between unexpected weight loss & cancer
/in Front page /by Oxford CentreNew research will help GPs to identify the signs they should look for to swiftly diagnose cancer in people with unexpected weight loss
TP53 gene determines severe blood cancer development
/in Front page /by Oxford CentreA new study has found that the allelic appearance of the TP53 gene has great impact on development of severe types of blood cancer
Using DNA & RNA to treat cancers
/in Front page /by Oxford CentreCancer research UK Oxford Centre Development Fund Awardees Ysobel Baker and Tom Brown investigate the potential of DNA and RNA molecules as precision cancer treatments
Quick Links
LATEST NEWS
CONTACT
You can keep in touch in a number of ways:
- Visit the contact page
- Tel: 01865 617043
- cancercentre@oncology.ox.ac.uk
- View the locate Centre page
OUR PARTNERS
